ERG is a leading U.S. based, privately held, independent clinical research site company, and provider of clinical development services with an expertise in early and late stage neuroscience drug development. With 21 wholly owned clinical sites and 5 affiliated sites, we conduct in-patient and out-patient phase I-IV clinical research studies. ERG has 340+ in-patient beds, a large and growing database of patients suffering from mental illness, neurological disorders, sleep disorders, addictions, Acute and Chronic Pain, diabetes and other illnesses as well as normal healthy volunteers who participate in trials for the advancement of medicine. With access to over 32 million patients/subjects and 5000 + completed trials, ERG continues to grow its capabilities and expand into indications where there are tremendous unmet medical needs in the United States and globally. The ERG portfolio of sites we own consists of Woodland International Research Group, Woodland Research Northwest, Midwest Clinical Research, Pacific Research Network, Clinical Pharmacology of Miami, Brain Matters Research, Neuropsychiatric Research Center, Richmond Behavioral Associates, Finger Lakes Clinical Research, Endeavor Clinical Trials, and HD Research, all supported by an industry leading centralized infrastructure located in New Jersey. ERG offers consulting services to pharmaceutical and CRO clients, including access to key opinion leaders in Schizophrenia, Pain, Alzheimer’s disease, Sleep Disorders, Depression, Hepatic/Renal Impairment, Podiatry and Clinical Pharmacology. This includes Rater Training Services, Centralized Data Services (ECG, PSG, EEG, qEEG, Actigraphy), Medical Writing Services, Study Feasibility and Site Recommendation ERG also offers general consulting in study design, protocol review and budget planning, vendor resources, Scientific Advisory Board Planning and Implementation, study feasibility and site recommendations.